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Abstract 
The short term and long term benefits to mother and baby with breastfeeding are well-
documented, however, the actual rates of exclusive breastfeeding to 6 months of age are less than 
17% in Canada. The most often cited reason for discontinuation of breastfeeding is not enough 
breastmilk, which has increased the use of galactagogues- substances used to induce or augment 
lactation in breastfeeding women. There is a lack of guidance regarding the appropriate use of 
galactagogues because at present there is only one clinical practice guideline from the American 
Academy of Breastfeeding Medicine (ABM) which does not describe actual use in practice and 
has not been updated since 2004. This has resulted in practice based on anecdotal evidence, with 
a wide variation in indications, dosages, and duration of treatment among primary care 
practitioners. A literature review of galactagogue use and research from 2000 to 2010 was 
performed, grey literature such as presentations, theses and dissertations were included, and 
practitioners were interviewed regarding their own use of galactagogues in practice. In Canada 
the most widely used galactagogues are the herb fenugreek, and the medication domperidone. 
Fenugreek has not had any randomized controlled trials (RCT) to support its safety or efficacy in 
practice, which makes its recommendation more difficult, particularly because it has been 
reported to have significant side effects such as hypoglycemia. Conversely, domperidone has 
been shown to be safe and effective, with low incidence of side effects. Domperidone is used 
widely in Canadian practice for this off-label purpose by physicians and nurse practitioners (NP). 
When accompanied by assessment and treatment of underlying physiological causes of breast 
milk insufficiency and or milk transfer issues such as poor infant latch, domperidone I 0 mg 
three times daily with thorough assessment and follow up is a reasonable and safe galactagogue 
choice. 
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Research that clearly demonstrates the benefits and superiority of breastfeeding over 
breast milk substitutes has led in recent years to an increase in the number of women who choose 
to breastfeed their babies, and has increased societal pressure on all women to do the same. 
Breastfeeding has become more of an infants ' rights issue than a choice for women, an almost 
complete reversal of the women's rights movements only five decades ago that viewed 
breastfeeding as tying women down, and glamorized the modern household in which babies were 
bottle-fed (Thulier, 2009). "Baby-Friendly" initiatives now encourage hospitals to ban all breast 
milk substitutes and artificial nipples from their premises, and the slogan "Breast is Best" are 
seen on posters everywhere mothers and babies are likely to be found. While there is no denying 
the benefits of breastfeeding for both mother and baby, this increased pressure to succeed at 
breastfeeding has created a niche market of herbal , alternative, and pharmaceutical treatments 
that claim to increase maternal breast milk production through a variety of mechanisms. Despite 
the increasing demand for these products from breastfeeding mothers, the development of 
evidence-based guidance regarding how to safely prescribe galactagogues has not kept pace with 
this demand , and anecdotal evidence is often used as the only resource for practitioners . 
Galactagogues are not a new concept, and cultures around the world have a variety of methods to 
increase maternal breast milk production. However, based on my own experience, and from 
speaking with primary care providers, nurse practitioners (NP) frequently find themselves in the 
position of being asked for their advice regarding herbal or alternative galactagogues, and 
responsible for prescribing pharmaceutical galactagogues. 
NPs have only been legislated to practice in British Columbia (BC) since 2005 (Canadian 
Institute For Health Information, 2006), and as relatively new primary care providers, often 
access guidelines to ensure that they provide the best poss ible care using the latest evidence. 
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NPs working in primary care certainly may have patients who request treatment for insufficient 
milk supply. The lack of up-to-date information and direction regarding appropriate assessments 
and treatment for this condition, including the use of such commonly prescribed treatments as 
galactagogues, is a concern. This paper will include a review and critique of the latest research 
findings on galactagogues that are commonly used in Canada, as well as the guidelines that are 
currently available. Recommendations for practice will be presented based on these findings in 
an attempt to provide that missing guidance for appropriate and safe prescribing of 
galactagogues by NPs. 
Literature Review 
Information for this project was found using the search engines Medline, CINAHL, and 
Google Scholar. The key words used to search for information were galactagogues, 
galactogogues, breast feeding, lactation, augmentation, and gal act*. Terms of exclusion were 
adoption, as the focus of this project was on the augmentation rather than the induction of 
breastfeeding and maternal milk supply. Only papers published from 2000 to 2010 were 
included in the literature search, and only those that were available in English whether translated 
or not, with the intent of including only the most current information and research. The 
reference lists of all accepted articles were used to find additional evidence. This process was 
continued until the results became repetitive, with several key articles becoming apparent. 
Personal communications in the form of email and personal interviews were used when 
no published information was available, and dissertations and theses were accepted. The wide 
range of acceptable literature for this project was a result of the difficulty in finding current 
research on this topic. The idea for this project arose from previous paper written in which the 
clinical practice guideline for galactagogue use were analyzed and critiqued. This critique 
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brought to light the lack of consensus regarding galactagogue use, and the fact that anecdotal 
rather than research-based evidence was being used to guide clinicians in their decisions 
regarding when and how to prescribe galactagogues. 
The supporting literature for breastfeeding self-efficacy, which is defined as maternal 
confidence in the ability to breastfeed (Dennis, 1999), was found during research for a previous 
paper, and the physiology of breastfeeding information was gleaned from the galactagogue 
literature, as well as current textbooks that were frequently cited in this same literature. 
Resources were not exhausted with regard to supporting literature, but stopped searching stopped 
when information became repetitive. Canadian sources were used preferentially over American 
or international references whenever possible, and the breastfeeding recommendations are from 
current Health Canada literature. 
Clarification of Terms 
To avoid potential misunderstandings, the following terms require a brief explanation of 
how they are defined for this particular paper. The terms primary care and primary health care 
are often used interchangeably. For the purposes ofthis paper, the definition of primary health 
care will be that of the World Health Organization ' s (WHO) Declaration of Alma-Ata: 
"Primary health care is essential health care based on practical , scientifically sound and 
socially acceptable methods and technology made universally accessible to individuals 
and families in the community through their full participation and at a cost that the 
community and country can afford to maintain at every stage of their development in the 
spirit of self reliance and self-determination. It forms an integral part both of the country's 
health system, of which it is the central function and main focus, and of the overall social 
and economic development of the community. ft is the first level of contact of 
individuals, the family and community with the national health system bringing health 
care as close as possible to where people live and work, and constitutes the first element 
of a continuing health care process." (WHO, 1978, p. 2) 
The definition of primary care for this paper therefore is that it is an integral part of 
primary health care, the main entry point or primary level of contact of individuals and or 
families to the national health care system (Thomas-Maclean, Tarlier, Ackroyd-Stolarz, Fortin, 
& Stewart, 2008). In other words, primary care settings are where primary health care takes 
place, and primary care providers offer primary health care. 
The term successful breastfeeding will refer to exclusive breastfeeding of infants to 6 
months of age, which means no supplemental feeds with breast milk substitute, but may include 
expressed breast milk given by bottle. After 6 months of age, solids are recommended to be 
introduced and exclusive breastfeeding is no longer the recommendation (Health Canada, 2004). 
Galactagogues are defined as medications, substances, or treatments that are used to initiate, 
stimulate, increase, enhance, or maintain maternal milk supply for the purposes ofbreastfeeding 
(The Academy Of Breastfeeding Medicine (ABM) Protocol Committee, 2004; Anderson & 
Valdes, 2007; Betzold, 2004; Brodribb, 2000; Gabay, 2002; Henderson, 2003; Low Dog, 2009). 
Background 
Benefits of Breastfeeding 
The benefits to newborns of exclusive breastfeeding have been reported and include, but 
are not limited to decreased incidence of gastrointestinal , upper respiratory, and otitis media 
infections; decreased incidence of sudden infant death syndrome, prevention of allergies, 
improved cognitive development demonstrated by higher scores on IQ tests as well as academic 
performance in school, and increased contact between mother and newborn (Public Health 
Agency of Canada (PHAC), 2009; Health Canada, 2005 ; Health Canada, 2007; Kramer & 
Kakuma, 200 I). 
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Maternal benefits include decreased incidence of breast and ovarian cancer and 
osteoporosis, delayed onset of menses, and increased and more rapid weight loss in the 
postpartum period (Health Canada, 2009a; Kramer & Kakuma, 2001 ). Bartick and Reinhold 
(2010) performed a pediatric cost analysis and determined that if90% of American families 
could exclusively breastfeed their infants for 6 months, the United States (US) would save 13 
billion dollars in health care costs and prevent 911 deaths, most of them infant deaths. 
Environmental benefits include no processing, no packaging, and no waste, as well as the cost-
benefits, which are considerable (PHAC, 2009). The Infant Feeding Action Coalition (INF ACT) 
Canada (1997) surveyed formula costs across the country based on income assistance for a single 
mother, and determined that there was great variation in formula prices, 5%-34% of the monthly 
income, depending on the geographical location and demand for formula in that area. The most 
expensive locales were remote areas with associated decreased rates of breastfeeding. This led 
INFACT to the realization that " [the formula] industry varies its prices according to the degree 
of competition presented by breastmilk." (IN FACT Canada, 1997). Breastfeeding for 
socioeconomically disadvantaged families, particularly those in rural and remote areas, may 
mean the difference between food security or insecurity for the entire family. 
Adults who were breastfed as infants, when compared with control groups who were not 
breastfed , had lower systolic and diastolic blood pressure (Martin, Gunnell, & Smith, 2005), 
lower mean total cholesterol levels, were less likely to be overweight or obese, less likely to be 
diagnosed with Type 2 diabetes mellitus, score higher on intelligence tests, and obtain better 
grades in school (Hotia, Bahl , Martines, & Victora, 2007). While the direct costs to the health 
care system have not been spec ifically measured , the decrease in chronic disease cannot help but 
to lessen the burden on the system. 
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In 2004, Health Canada changed the recommended duration of exclusive breastfeeding 
from 4-6 months to 6 months of age, in line with the WHO 2001 recommendation (Health 
Canada, 2004). Despite the recommendations and acknowledged benefits to both mother and 
baby, while 85% of Canadian women in 2003 initiated breastfeeding, only 17% breastfed 
exclusively for at least six months. British Columbia (BC) had the best initiation and duration 
rates, with 93% of women initiating breastfeeding, and 28% exclusively breastfeeding for at least 
six months (Millar & Maclean, 2005). Interior Health Authority in BC notes an 89% initiation 
rate with 53% of women doing some breastfeeding at six months postpartum (Bryan, 2005), 
unfortunately there is no indication of whether or not this is exclusive breastfeeding. For those 
women who did not breastfeed exclusively for the recommended six months, the most commonly 
cited reason for stopping breastfeeding was "not enough milk" (Millar & Maclean, 2005, p. 27), 
at 31%. Similar statistics are noted in Australia, the US, and the United Kingdom (UK) with 
fewer than 23% of women maintaining any breastfeeding to six months postpartum, and only 
50% of women exclusively breastfeeding to six months in developing countries (Blyth et al., 
2002) . 
Physiology of Breast Milk Production 
Lactogenesis takes place in two stages. Lactogenesis I occurs during the second trimester 
of pregnancy, whereby the formation and expansion of ducts and lobules occurs, and epithelial 
cells of the alveoli differentiate into secretory cells (Biancuzzo, 2003; Riordan, 2005). Prolactin 
is released from the anter ior pituitary gland and stimulates the production of colostrum (Eglash, 
Montgomery, & Wood, 2008; Riordan, 2005). The amount of colostrum produced is small , and 
it is hypothesized that hi gh leve ls of estrogen and progesterone during pregnancy inhibit the 
action of prolactin on milk production prior to delivery of the placenta (Berens, 2004; Gabay, 
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2002). Lactogenesis II is the onset of copious milk production, occurs after delivery of the 
infant (and perhaps more importantly the placenta), and may take up to eight days postpartum to 
be fully achieved (Riordan, 2005). 
The delivery of the placenta causes a sharp drop in progesterone levels and thereby 
removes that antagonism from the effect of prolactin, which increases milk supply (Berens, 
2004; Eglash et al., 2008; Hurst, 2007). This occurs simultaneously with a change in the 
composition ofthe breastmilk to one high in lactose and milk lipids, and lower in sodium, 
chloride and protein. This is a result of junction complex closure between alveolar cells, which 
allows for passage of substances between these alveoli (Riordan, 2005). 
Full realization of lactogenesis II and continuation of milk production during the first 
three to five days postpartum are dependent on the feedback mechanism of milk removal from 
the breast. This occurs with supply and demand infant suckling and feeding, or mechanical 
pumping of the breast if infant feeding is not possible (Eglash et al., 2008). When the nipple is 
stimulated by infant suckling or mechanical pumping, and milk is removed from the breast, the 
hypothalamus inhibits dopamine, which allows for increased release of prolactin from the 
anterior pituitary, and therefore increased milk production (Riordan, 2005). Nipple stimulation 
also causes release of oxytocin from the posterior pituitary, which helps with milk secretion or 
" let down" by causing contraction of myoepithelial cells in the breast (Gabay, 2002). The 
culmination of these processes is a switch from the initial process of endocrine-controlled 
lactation, which all women experience immediately postpartum whether they breast feed or not, 
to the secondary and long-term process of autocrine-controlled lactation, which can only be 
maintained through continued breast milk removal (Mohrbacher & Stock, 2003). While this 
provides a rather simplified exp lanation of materna l milk production, a more detailed account of 
the process is outside the scope of this project. Rather, this brief explanation can suffice to 
demonstrate how NPs might explore possible causes of insufficient milk supply in women and 
consider the various causes. 
Causes oflnsufficient Nutritional Status in Newborns 
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There are three possible physiological mechanisms for insufficient nutritional status of a 
breastfed newborn. The first is primary failed or delayed lactogenesis II, and while the actual 
rates are unknown, it is estimated that between 5% and 15% of women will experience one of 
these circumstances (Hurst, 2007). Recall that lactogenesis II is the transition from hormonally-
induced production of colostrum during pregnancy to milk production following delivery. Hurst 
differentiates between delayed and failed lactogenesis II, with the implication that delayed 
lactogenesis, defined as later than 72 hours after delivery (Riordan, 2005), can still progress to 
full and successful lactation, while failed lactogenesis II is further broken down into either a 
"primary inability to produce adequate milk volume, or a secondary condition as a result of 
improper breastfeeding management and/or infant-related problems"(Hurst, 2007, p. 589). 
There are numerous conditions that may impact on the ability to attain lactogenesis II. 
The intricate interplay of hormones required to produce breast milk can be interrupted by any 
condition that is hormonal in nature such as obesity, thyroid abnormalities, and diabetes (Hurst, 
2007). Women with Type I diabetes mellitus have lower levels of prolactin in their breast milk 
and this can cause a delay in lactogenesis II. Women with polycystic ovarian syndrome or theca 
lutein cysts have higher levels of testosterone, which may interfere with the hormones required 
for lactogenesis II and lead to a delay. Postpartum hemorrhage can lead to Sheehan syndrome, 
which affects pituitary gland function and therefore prolactin and oxytocin secretion (Hurst, 
2007). Retained placental fragments may secrete sufficient progesterone to impair prolactin 
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release and thereby interfere with lactogenesis II. Cesarean birth, prolonged second stage of 
labour, and maternal stress may increase cortisol levels, which is thought to be associated with 
delayed lactogenesis II (Riordan, 2005). Women with anatomical breast abnormalities such as 
insufficient mammary glandular tissue, or those who have experienced invasive breast surgery 
such as augmentation or reduction, may have physical disruptions in normal lactation. Finally, 
cigarette-smoking and administration of hormonal contraceptives during the first week 
postpartum also decrease prolactin secretion and therefore breast milk production (Hurst, 2007). 
The second cause of insufficient nutritional status of a breastfed newborn is secondary 
delayed lactogenesis related to breastfeeding management or breast milk transfer issues. This can 
comprise delayed breastfeeding initiation due to maternal-infant separation secondary to any 
number of causes, including cesarean section, prolonged second stage of labour, preterm 
delivery, maternal or newborn ill health, which can delay onset of lactogenesis II, and feeding 
infrequently or supplementing with breast milk substitutes, which leads to decreased prolactin 
release and therefore delayed lactogenesis II. Poor infant latch secondary to tongue tie, 
congenital malformations such as cleft palate/ lip, prematurity, ill health, jaundice, congenital 
heart defects , or poor overall breastfeeding technique can lead to decreased milk transfer, or 
removal of breast milk from breast, decreasing prolactin secretion and thereby delaying 
lactogenesis II (Hurst, 2007). 
The third cause of insufficient nutritional status of a breastfed newborn is organic failure 
to thrive, which means that there is a pathophysiological reason that the newborn is not gaining 
weight. This category encompasses a variety of congenital conditions such as: gastroesophageal 
reflux; pyloric stenosis; lactose intolerance; Hirschsprung disease; milk protein intolerance; liver 
disease; pancreatic disease; kidney disease; cardiopulmonary disease; thyroid disorders; cerebral 
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hemorrhage; mental retardation; bacterial or parasitic infections of the gastrointestinal tract; 
inborn errors of metabolism; chromosomal abnormalities; as well as a variety of congenital 
syndromes (Evers, 2006; Petersen-Smith & McKenzie, 2009). It is beyond the scope ofthis 
paper to discuss the myriad of factors that may affect a newborn's ability to breastfeed and or to 
metabolize breastmilk successfully, however it is extremely important that any 
pathophysiological cause be ruled out during the initial breastfeeding assessment of a mother-
baby dyad. 
Perceived Versus Actual Breast Milk Insufficiency 
Perceived or actual insufficient milk supply is described in numerous studies as a 
common, if not the most common, reason for breastfeeding discontinuation (Dyson, McCormick, 
& Renfrew, 2009; Flidel-Rimon & Shinwell, 2006; Lewallen et al., 2006; McCarter-Spaulding & 
Kearney, 200 l; Sakha & Behbahan, 2008). Perceived breast milk insufficiency is defined as 
"the mother's belief that her breast milk is inadequate in amount or nutritional quality to meet 
her infant's needs" (McCarter-Spaulding & Kearney, 2001 , p. 517), and is closely linked to 
confidence, support, and self-efficacy (Chung, Raman, Trikalinos, Lau, & Jp, 2008; McCarter-
Spaulding & Kearney, 200 I); while poor latch at the breast, maternal medical conditions, some 
medications, and disruptive health care practices are associated with actual breast milk 
insufficiency as discussed previously (Berens, 2004; Hurst, 2007; Meier, Furman, & Degenhardt, 
2007). 
The perception of insufficient maternal milk supply is intertwined with the western 
cultural ideals placed on objective measurements for data. Women and families are 
uncomfortable with not knowing exactly how much breastmilk the infant is receiving (Lewallen 
et al., 2006). When mothers perceive that their milk supply is insufficient, they often respond by 
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supplementing unnecessarily with formula, which interferes with the intricate feedback 
mechanism that influences maternal milk production as discussed previously, creating a situation 
of actual milk insufficiency (McCarter-Spaulding & Kearney, 2001). lfthe baby does not show 
any signs of dehydration, is gaining weight, and has adequate output, then there is no problem 
with milk insufficiency, no matter what the duration or frequency of feeds are. In this case, logic 
would suggest that the mother requires reassurance and education only. For this reason it is 
extraordinarily important to educate women regarding variety of feeding patterns among babies, 
and the reassuring signs of adequate intake and growth. 
Another consideration is the cultural, societal, public health pressure to breastfeed that is 
experienced by women. In her summary of the history of breastfeeding in America, Thulier 
(2009) observes that research regarding the benefits of breastfeeding to both mother and baby, 
the increasing awareness of child health issues, and the need to contain costs to the health care 
system have led to the current wave of breastfeeding promotion and awareness campaigns from 
all sectors of health care. "Breast is Best" is arguably one of the best known health care slogans 
in our society. Perhaps the movement toward more natural , organic foods, and the sense of 
distrust and disillusionment with mega-corporations such as Nestle have also contributed to the 
increasing trend to breastfeed (Baby Milk Action, n.d.; Breastfeeding.com, n.d. ; International 
Baby Food Action Network (IBFAN), n.d.). 
Women who are unable to breastfeed for any number of reasons may find themselves 
dealing not only with an internal sense of failure, but with a societal burden wherein their sense 
of worthiness as a mother is challenged because they are not doing what they may strongly 
believe is "best" for their baby. Saisto, Salmela-Aro, Nurmi, and Halmesmaki (2008) found that 
women who experienced breastfeeding as pleasant suffered less parental stress when their 
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children were toddlers compared to parents who had difficulty breastfeeding, and Health 
Canada (2005) has listed "added self-esteem for mother" as a benefit of breastfeeding, and 
boldly claim that "mothers often like it more than bottle feeding". This leaves women who are 
unable or unwilling to breastfeed at risk for feelings of inadequacy and being abnormal. Women 
may find themselves going to extraordinary lengths to succeed at breastfeeding as a way to prove 
that they are good mothers (Ryan, Bissell, & Alexander, 2010). The other side ofthis coin is 
women who choose to bottle feed against health care provider advice, and are forced to justify 
this decision in the face of societal pressure to breastfeed (Ryan et al. , 20 I 0) . It could be argued 
that this is another reason for perception of breast milk insufficiency, as inadequate breast milk 
supply might be viewed as an acceptable reason to not breastfeed, giving women a way out of 
the moral dilemma. 
Ryan et al. highlight the moral work that women undergo when making decisions around 
how to feed their infant with the statement, "They are social and moral actors in both private and 
public realms , disciplining their bodies and minds to meet social expectations and preserve their 
social identity and moral integrity while balancing past, present and future self-concepts ." (Ryan 
et al. , 2010, p. 955). Tn other words, the decision to breastfeed is not simply a private, family 
matter, but also one made in the public arena and open to public scrutiny and judgement. 
Mothers ofpreterm infants and multiples are even more vulnerable to this public and medical 
pressure as they begin their role as a mother with no privacy, but instead under the " institutional 
authority" and constant observation (Flacking, Ewald, & Starrin, 2007, p. 2405) of health care 
providers in the neonatal intensive care unit, where staff are advised to "actively encourage" 
mothers of preterm and multiples to breastfeed (British Columbia Perinatal Health Program 
(BCPHP), 2007) . 
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The pressure to successfully breastfeed, from almost all facets of society and 
government on both local and global scales has ensured that medications and herbs that induce or 
augment lactation have an excellent marketing niche, as well as buy in from both prescribers and 
patients. The prescribing of galactagogues has become commonplace, particularly in situations 
known to be challenging for breastfeeding, with much of the literature regarding galactagogue 
use discussing its use in mothers ofpreterm infants and multiples (Albright, 2004; Campbell-Yeo 
et al., 2010; da Silva, Knoppert, Angelini, and Forret, 2001 ; Henderson, 2003; Leonard, 2002; 
Newman, 2003; Wan et al. , 2008) , but also in low risk mother baby dyads that have developed 
breast milk insufficiency secondary to poor breastfeeding management, poor breastfeeding 
support, or medications. 
There are a number of reasons for the increasing use of galactagogues, despite the fact 
that they really should only be used as a last resort. We live in a society that is accustomed to 
medical treatment in all facets of our health, and so readily accept medications as a solution. A 
societal discomfort with not knowing how much breast milk a baby is receiving with each feed , 
and our perception of babies as chubby and cherubic so that when they are more slender and do 
not fit that stereotype, leads to unwarranted concern and a desire to fix a problem that does not 
exist. Finally primary care providers may not ascribe the same importance to knowledge of the 
normal physiology of breastfeeding as they do to the pathophysiology of disease because of the 
perception that this is a natural process. Unfortunately this rather laissez-faire viewpoint, much 
the same as that toward herbal and alternative remedies, leads to anecdotal and personal 
experience guiding practice rather than evidence, and the subsequently wide variation in practice 
with regard to galactagogues that presently exists. 
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Herbal Galactagogues 
There are numerous herbal remedies and recipes used all over the world to increase milk 
supply. For the purposes of this paper, I have chosen to focus on fenugreek and blessed thistle, 
the two most commonly recommended herbal galactagogues in Canada (ABM, 2004; Mallory, 
2008; Newman, 2003b). 
Fenugreek 
Fenugreek, or Trigonellafoenum-graecum, is native to southern France, Turkey, northern 
Africa, India, and China (D'Itri, 2006). It is eaten as a vegetable in India and Egypt, and is used 
extensively in Indian and Chinese medicine for many reasons including induction of labour, help 
with digestion, to improve overall health and metabolism, as a poultice to treat skin 
inflammations, to treat abdominal pain, impotence, hernias, fever, vomiting, anorexia, weight 
loss, coughs, bronchitis, colitis, to decrease serum cholesterol and glucose levels, reduce 
vasomotor symptoms in perimenopausal women, treat hair loss in both men and women, and as a 
lactation aid (Abascal & Yarnell , 2008; D' ltri , 2006; Low Dog, 2009; Ulbricht et al., 2007). 
While the mechanism of action is not known, it is speculated that the galactagogue effect is 
related to the herb's ability to increase sweat production, with the breast being a modified sweat 
gland (Curtis, n.d.; Gabay, 2002; Huggins, n.d.; Mallory, 2008) 
Fenugreek is usually recommended to be taken two to three times per day when used as a 
galactagogue, however there is little agreement on how much should be taken at each dose, with 
a range of 400-2400 mg, and acknowledgement that because these are herbal preparations that 
are not standardized, it is difficult to know for cetiain what dose the patient is taking at any time 
(Abascal & Yarnell, 2008; ABM, 2004; Curtis, n.d.; D'Itri , 2006; Gabay, 2002; Huggins, n.d.; 
Low Dog, 2009; Mallory, 2008; Mohrbacher & Stock, 2003; Newman, 2003b). Most sources 
claim that fenugreek may be discontinued once adequate breast milk supply has been 
established, but there is disagreement in the literature regarding whether fenugreek can be 
stopped abruptly or should be weaned off over one week (Curtis, n.d.; Gabay, 2002; Huggins, 
n.d.; Newman, 2003b). 
20 
The side effects of fenugreek are described as a maple syrup odour to urine, sweat, and 
breast milk; diarrhea; aggravation of asthma; and hypoglycemia (ABM, 2004; Curtis, n.d.; D'Itri, 
2006; Gabay, 2002; Huggins, n.d.; Mallory, 2008; Tiran, 2003; Ulbricht et al., 2007). The babies 
of women taking fenugreek can also have urine that smells like maple syrup, and there is some 
theoretical risk that these babies could be mistakenly diagnosed with maple syrup urine disease 
(Abascal & Yarnell, 2008; Laurence, n.d.; Low Dog, 2009). Other potential concerns with 
fenugreek use are allergic reactions, uterine contractions, and an interaction with warfarin that 
increases its anticoagulation effect. For these reasons is not recommended in women who are 
pregnant, diabetic, asthmatic, who have cardiovascular disease, or previous gastrointestinal 
disease (ABM, 2004; D' ltri, 2006; Gabay, 2002; Tiran, 2003; Ulbricht et al., 2007). 
There are two citations referred to often in the literature as preliminary reports that 
reportedly demonstrate the effectiveness of fenugreek (Co, Hernandez, & Co, 2002; Swafford & 
Berens, 2000). Unfortunately it was not possible to locate the report by Co, Hernandez, and Co, 
but Dr. Berens was kind enough to e-mail a copy of the unpublished presentation delivered by 
herself and Dr. Swafford. Swafford and Berens measured breast milk production in ten women 
who were at least 14 days postpartum, with infants born 28-38 weeks gestation. The study took 
place over two weeks. The first week the women pumped and measured the volume of breast 
milk as a baseline, the second week they took three fenugreek capsules three times daily and 
measured their breast milk using the same pumps. The average volume of breast milk pumped 
daily increased from 207 ml in the first week to 464 ml in the second week. There is no 
mention of whether this was exclusive pumping, or following a feed, and it is difficult to know 
how much of this increase can be attributed to fenugreek versus a natural increase based on 
supply and demand without a control group against which to compare these results. 
Another frequently cited study on the use of fenugreek is Huggins (n.d.), who discusses 
anecdotally that among approximately 1200 women with whom she has worked and who have 
taken fenugreek, "Nearly all of the mothers ... report an increase in milk production, generally 
within 24-72 hours" (Huggins, n.d.). It is impossible at this point to know if this increase is 
actual or perceived. Newman (2003b) states, "If they [fenugreek and blessed thistle] do work, 
you will usually notice a difference within 3 to 4 days ... lfnot, they probably won't work." 
(Handout #24). Laurence notes (n.d.), again anecdotally, that her results with fenugreek have 
been mixed, with some mothers rep01ting no change in milk supply and others reporting 
significant increases. 
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Fenugreek is listed as Generally Recognized As Safe by the US Food and Drug 
Administration (US FDA, 20 l 0), and Health Canada (2009c) also has minimal concerns 
regarding its use although they do not have a list of safe herbs per se and they do not require any 
safety trials or standardization for fenugreek to be sold in Canada. 
Blessed Thistle 
Blessed thistle, or Cnicus benedictus, is an herb that has no listed uses other than as a 
galactagogue, and it is often recommended to be taken along with fenugreek, with Newman 
(2003) claiming that the two herbs work better together. Abascal and Yarnell (2008) include a 
recipe for " More Milk Plus" tincture that contains fenugreek, blessed thistle , stinging nettle, and 
fennel. The mechanism of action is not listed in the literature so is presumed to be unknown. 
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The recommended dosage is three capsules three times daily or 20 drops of tincture 
three times daily. The outcome is suggested to be similar to fenugreek, with increased maternal 
milk supply noted, albeit subjectively, within 3-4 days (Mallory, 2008; Newman, 2003b). 
Reported side effects include vomiting and diarrhea when taken in amounts greater than 5 grams 
per dose. (Mallory, 2008; Newman, 2003b). There were not any studies on blessed thistle found 
in the literature. 
Health Canada (2008a) has a warning on the product monograph for blessed thistle, 
stating: "Consult a health care practitioner prior to use if you are breastfeeding", and that it 
should not be used during pregnancy. This monograph does not list lactation as an indication for 
use of blessed thistle. 
Other Herbal Galactagogues 
Additional herbs that are mentioned briefly in the literature include: Goat's rue (Galega 
officina/is); Fennel seed (Foeniculum vulgare); Chaste tree seed (Vitex agnus-castus); wild 
asparagus roots (Aspragus racemosus); aniseed (Pimpinella anisum); fireweed (Epilobium); 
stingi ng nettle (Urtica dioica) ; caraway seed; cinnamon; dill ; raspberry leaf; brewer ' s yeast; 
alfalfa (Medicago sativa); cotton root (gos.sypium); borage leaves (Borago officina/is); hops 
(Humulus lupulus); basil; marshmallow (Abascal & Yarnell , 2008; ABM, 2004; Low Dog, 2009; 
Mallory, 2008; Newman, 2003b). These herbs have only anecdotal evidence describing their use 
as galactagogues. 
There is a small study in Peru that examined the effect on human milk production of 
micronized Silymarin, an extract of milk thistle, that has demonstrated success in increasing milk 
production in cows. DiPierro, Ca llegari, Carotenuto, and Mollo Tapia (2008) noted an increase 
in breast milk production of 85.95% in the women taking si lymarin compared with 32.09% in 
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the placebo group from day of delivery to day 63 postpartum, with no difference in milk 
composition. The mechanism of action is unknown, although it is hypothesized that there is an 
effect on estrogen that may increase milk production. There are no known side effects (Di Pierro 
et al., 2008). 
Alternative Non-Pharmaceutical Galactagogues 
There are two other complementary or alternative methods of augmenting breast milk 
production that were mentioned frequently in the I iterature, therefore a brief discussion of the use 
of alcohol and acupuncture to increase breast milk production is included. 
Alcohol 
Alcohol is considered a galactagogue in many cultures, including North America, and 
many women report that they were told by their primary care provider that alcohol, particularly 
barley-based alcohol such as beer, will increase milk production and assist with milk let-down 
(Giglia & Binns, 2007; Mennella, 2001; Mennella, Pepino, & Teff, 2005). This is despite the 
fact that there is no evidence to support this theory, and in fact , current research suggests just the 
opposite. 
Mennella (200 I) notes that studies have demonstrated that infants consume, on average, 
20% less breastmilk in the 3 to 4 hours after maternal alcohol consumption, compared with 
regular feedings. This is not related to the feeding time, or refusal to nurse, but rather to 
maternal breast milk production. Alcohol seems to inhibit suckling-induced prolactin 
production, oxytocin release, and subsequently milk production and infant intake, although it has 
no effect on baseline prolactin levels (Mennella et al., 2005). 
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Acupuncture 
It was difficult to find English-language studies examining the effect of acupuncture on 
lactation, however there are Chinese-to-English translated abstracts available that claim to 
increase milk production using acupuncture (Wang & Li, 2004; Wei, Wang & Han, 2007), 
although it is difficult to determine how increased milk supply was measured. As well, there 
have been two recorded case studies of inadvertent induction of lactation following acupuncture 
treatments in women who were not lactating at the time of treatment (Campbell & Macglashan, 
2005; Jenner & Filshie, 2002). 
Li's (n.d.) dissertation on the effect of acupuncture on increasing the milk supply of 
lactating women claims that traditional Chinese acupuncture increased infant weight gain and 
decreased need for supplementation with formula. Her assumption is that this weight gain is 
related to maternal milk production. This was a pilot study consisting of27 women in a single 
blind controlled trial. It is unfortunate that maternal milk production was not measured in a more 
objective manner such as pumping. 
Pharmaceutical Galactagogues 
The two most frequently discussed pharmaceutical galactagogues in the literature are 
metoclopramide and domperidone. In Canada domperidone has become the more widely used of 
the two, because it does not cross the blood-brain barrier and so has fewer central nervous 
system side effects when compared to metoclopramide. 
Metoclopramide 
Metoclopramide is a central nervous system dopamine-antagonist that was originally 
promoted and sold as an antipsychotic in Europe; however it has been most recently used in 
North America as a gastric motility agent for treatment of nausea, vomiting, and 
gastroesophageal reflux (ABM, 2004; Anderson & Valdes, 2007; Betzold, 2004; Brodribb, 
2000; Gabay, 2002). The off-label use of metoclopramide as a galactagogue has been reported 
and studied since 1975 (Anderson & Valdes, 2007). It is frequently described as the most 
commonly used medication to induce or augment lactation in the US (ABM, 2004; Henderson, 
2003). The mechanism of action for metoclopramide with regard to inducing or augmenting 
lactation is the antagonism of dopamine- known to inhibit the release of prolactin from the 
anterior pituitary. This dopamine antagonism therefore increases prolactin levels, and 
subsequently increases breast milk production (Henderson, 2003; da Silva, 2004). 
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The most commonly prescribed dosage of metoclopramide as a galactagogue is l 0 mg 
orally three times daily (ABM, 2004; Anderson & Valdes, 2007; Henderson, 2003; Hsi & 
Leeman, n.d.). Possible side effects of metoclopramide include restlessness, anxiety, drowsiness, 
insomnia, fatigue, lassitude, dizziness, and Gl effects such as cramping and diarrhea (ABM, 
2004; Betzold, 2004; Brodribb, 2000; Henderson, 2003; Hsi & Leeman, n.d .). Metoclopramide 
may also increase maternal depression and risk for seizures, and so is not recommended for 
women with a known history of depression, psychosis, pheochromocytoma, or seizures (Betzold, 
2004; Henderson , 2003). This drug can have extrapyramidal side effects, including dystonic 
reactions (ABM, 2004; Gabay, 2002; Betzold, 2004; Hsi & Leeman, N.D.) and the US FDA has 
issued a black box warning stating metoclopramide should not be used for longer than 12 weeks 
at any dosage due to an increased incidence of extrapyramidal side effects with prolonged 
treatment (US FDA, 2009). 
Domperidone 
Domperidone is approved for use in Canada as a gastrokinetic medication with 
indications including treatment of motility disorders , nausea and vomiting, headache disorders 
associated with nausea and vomiting, gastroparesis, dyspepsia, gastritis, esophageal reflux, 
and in anorexia and bulimia to relieve bloating and constipation (ABM, 2004; Albright, 2004; 
Brodribb, 2000; Compendium of Pharmaceuticals and Specialties (CPS), 201 0; da Silva et al., 
200 I; Gabay, 2002; Henderson, 2003; Newman, 2003a). The CPS (20 1 0) does discuss the use 
of domperidone as a galactagogue, despite no official approval from Health Canada, stating, 
"[ d]omperidone has been used in nursing mothers to improve lactation." (p. 775). 
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Domperidone is a dopamine antagonist that does not cross the blood/brain barrier. The 
mechanism of action with regard to inducing or augmenting lactation is similar to 
metoclopramide in that it is the antagonism of dopamine- which inhibits the release of prolactin 
from the anterior pituitary. This dopamine antagonism therefore increases prolactin levels, and 
subsequently increases breast milk production (Albright, 2004; Betzold, 2004; da Silva, 2004; 
Gabay, 2002; Henderson, 2003; Hsi & Leeman, n.d.; Newman, 2003a; Ruddock, 2005; Wan et 
al., 2008). 
There are discrepancies in the literature regarding the dosage for domperidone when used 
as a galactagogue. Recommended dosages range from l 0 mg to 30 mg anywhere from two to 
four times daily (ABM, 2004; Albright, 2004; Anderson & Valdes, 2007; Brodribb, 2000.; da 
Silva, 2004; Gabay, 2002; Henderson , 2003; Newman, 2003a; Ruddock, 2005; Wan et al., 2008). 
Wan et al. (2008) tested both 30mg daily and 60mg daily dosing in their study, and found that 
the 60 mg dose only slightly increased prolactin levels compared to the 30 mg dose, while 
increasing the incidence and severity of side effects. The CPS (20 I 0) simply notes that "As a 
galactagogue, domperidone is usually given at an oral dose of 60 to 80 mg daily though 30 mg 
daily has been used". (p. 775). 
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Potential side effects of domperidone include: edema and palpitations (0.5%); 
headache (1.2%); insomnia, dizziness, thirst, lethargy, irritability, nervousness(< 1 %); acute 
dystonic reactions (rare in adults); skin rash, itching, urticaria(< 1%); breast enlargement, 
galactorrhea, menstrual irregularities, hot flushes, mastalgia, elevated serum prolactin ( 1.3%); 
dry mouth (1.9%); abdominal cramps, diarrhea, regurgitation, appetite changes, nausea, 
heartburn, constipation(< 1 %); stomatitis, conjunctivitis, urinary frequency, dysuria, leg cramps, 
asthenia, drug intolerance, elevation of AST, AL T, cholesterol(< 1 %) (CPS, 2010, p. 775). 
The effect of domperidone on prolactin levels and breast milk volume has been studied in 
two double-blind RCTs with placebo by da Silva et al. (2001), and Campbell-Yeo et al. (2010). 
da Silva et al.'s study, while small with only 21 women, demonstrated significantly higher 
prolactin levels and breast milk production in women in the domperidone group compared with 
women in the placebo group. Campbell-Yeo et al.'s study was slightly larger with 46 
participants, and examined mean breast milk volume pumped by mothers of preterm infants 
randomly assigned to receive either domperidone I 0 mg three times daily for two weeks or 
placebo. " Breast milk volumes increased by 267% in the domperidone-treated group and by 
18.5% in the placebo group" (Campbell-Yeo et al., 2010, p. e 107). There was no significant 
difference in breast milk composition when energy, fat, carbohydrate, sodium, and phosphate 
content were compared in breast milk from the two groups. (Campbell-Yeo et al., 2010). The 
patticipants in these studies had all delivered prematurely at 30-31 weeks gestation, and were 
entered in the study after demonstrating insufficient milk supply at three to five weeks 
postpartum. Both studies observed steady increases in breast milk volume in participants taking 
domperidone within 48 hours of initiation of the drug ( da Silva et al., 2001; Campbell-Yeo et al., 
2010). 
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Wan et. a! (2008) performed a double-blind, randomized crossover trial to examine the 
effect of dosage of domperidone on milk supply in six women. Breast milk volumes were 
measured on day 0 and day 7 of the study and were found to be statistically similar between the 
two groups, however the authors concede that this is likely due to the low power of their study 
with so few participants. It is interesting to note the authors' observation of a higher prevalence 
of side effects such as dry mouth, headache, and abdominal cramping in the group receiving 20 
mg three times daily compared with the group receiving 10 mg three times daily. 
Finally, Brown et al. (2000) examined the effect of parity on the response often non-
pregnant women to a single dose of one of the following: metoclopramide 5 mg, or 10 mg, or 
domperidone 10 mg. The authors found that among nulliparous women metoclopramide 10 mg 
had a more rapid onset of action and overall higher peak prolactin levels compared with the 5 mg 
dose or the domperidone. However, among multiparous women there was no difference in onset 
of action timing or peak prolactin levels between either the two doses of metoclopramide or the 
domperidone. The authors suggest that parity should be considered when determining which 
drug/dose to prescribe as a galactagogue. This information may be useful if prescribing 
galactagogues for nulliparous women who are adopting and wish to breastfeed, however this 
topic is outside the scope of this paper. The pertinent point for the purposes of this paper is that 
all l 0 women responded with increased prolactin levels to both of these drugs. 
In the past decade, domperidone has become widely used in practice in Canada for its 
off-label use as a galactagogue. While there are no statistics on actual number of prescriptions 
written for domperidone as a galactagogue, interviews were done with numerous practitioners 
regarding their own practice. Each of these practitioners, who were either NPs or physicians, 
had prescribed domperidone as a galactagogue, and had found it to increase milk supply, 
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however there was acknowledgement that simply increasing milk supply did not always solve 
the problem of insufficient nutrition in the newborn. It was recognized that other factors often 
contributed to breast milk insufficiency such as poor breastfeeding technique, and previous 
maternal breast surgery. Clinicians prescribed domperidone most frequently using the CPS as a 
resource for determining dosage, with no consensus as to the length of time women should be 
taking it, and all used infant weight gain as an indicator of efficacy. Domperidone is anecdotally 
considered a safe drug with an excellent side effect profile and therefore is more likely to be 
prescribed by practitioners, although most admitted to not having examined any research 
regarding domperidone as a galactagogue (A. Carter, personal communication, July 20, 2010; C. 
Lapadat, personal communication, March 12, 201 0; C. Evanson, personal communication, June 
3, 201 0; R. Klepsch, personal communication, March 10, 201 0; I. Scrooby, personal 
communication, July 14, 2010; V. Stafford, personal communication, March 22, 2010). 
Domperidone is not approved by the US FDA for any use at all; however women are able 
to obtain domperidone from other countries such as Canada, or through compounding 
pharmacies (Wlock, 2006) . This prompted the US FDA to issue a warning to women who are 
using or are considering using domperidone to augment or induce lactation. The warning is 
based on reported deaths following the administration of domperidone intravenously in patients 
who were receiving chemotherapy (US FDA, 2004). There have been no reported incidents with 
the oral route. The drug plasma levels in oral administration are approximately 80 to 150-fold 
lower than similar doses administered via the intravenous route. Domperidone's bioavailability 
is only 13% to 18% when administered orally, which is reported to be a marked difference from 
intravenous administration (Betzold , 2004; Ruddock, 2005). Campbell-Yeo et al. had begun 
enrollment in their study on domperidone in Canada when the US FDA warning was issued. 
While the study was placed on hold briefly, a No Objection Letter was issued by Health 
Canada October I, 2004, and ethics approval was reinstated for the study October 5, 2004 
(Campbell-Yeo et al., 2007). 
Less Commonly-Used Medications 
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Growth hormone, thyrotropin-releasing hormone, sulpiride, chlorpromazine, recombinant 
human prolactin, and oxytocin nasal-spray are also briefly mentioned in the literature 
(ABM,2004; Gabay, 2002; Sauberan & Wight, 2006), however these are not commonly used as 
galactagogues, and research is limited, therefore they will not be discussed in this paper. 
Summary of Present Research 
There is a considerable scarcity of evidence regarding the use of herbal preparations such 
as fenugreek, however there is a lot of unreferenced, personal anecdotal-based discussion of their 
use available from a large variety of sources. There have not been any RCTs done with any 
herbal preparations and the I iterature review for the use of fenugreek as a galactagogue is a 
conflicting one with many gaps. Many of the sources did not provide references, evidence, or 
sometimes even expla in the claims that were made. There was not a single study to support the 
safety or efficacy of blessed thistle as a galactagogue. This may be a result of the mentality that 
natural products are by their very nature safe and therefore do not require the same rigorous 
examination that pharmaceuticals are subjected to, which may lead to anecdotal evidence being 
viewed as satisfactory. 
To date the most compelling evidence for an herbal galactagogue comes from the RCT 
with placebo trial of s ilymarin, or milk thistle, in Peru (Di Pierro et al. , 2008), that enrolled 50 
women (higher than many of the pharmaceutical galactagogue studies) and demonstrated 
increase in milk supply through test-weighing of the infants as well as measured volumes of 
breastmilk pumped following feeds. It would be compelling to see these results repeated in 
further trials. 
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Current research would suggest that alcohol should not be touted as a galactagogue, that 
it actually decreases maternal milk production and breast milk intake by infants rather than 
improving it as is commonly suggested. In fact, more research needs to be done to determine 
possible effects on the breastfeeding infant who is exposed to alcohol through breast milk, as this 
may prove to actually be a harmful intervention. 
From the limited information currently available, acupuncture may improve maternal 
breastmilk production and therefore may be a potentially useful galactagogue. The safety profile 
of acupuncture is also reasonable, provided single-use disposable needles are used (Li, n.d.), with 
the only identified concern being that it simply may not work. More research with more 
objective means of determining milk production needs to be done. However, there does not 
appear to be any reason to actively discourage women from attempting this approach at this time 
with the proviso that there is limited evidence for the effectiveness of acupuncture in increasing 
milk supply. 
Metoclopramide remains prominent in the US literature, with the abundance of studies 
done in the 1970's and 1980 ' s cited as confirmation of its effectiveness as a galactagogue. 
However, there have been few recent studies performed and it is not widely used in Canada due 
to its higher incidence of side effects when compared to domperidone. 
The four most recent studies on domperidone use as a galactagogue all demonstrated that 
domperidone is effective in increasing prolactin levels and breast milk production compared with 
placebo or with no intervention (Brown et al. , 2000; Campbell-Yeo et al. , 20 I 0; DaSilva et al. , 
2001; Wan et al. , 2008). These studies were all randomized, which places them in the "good" 
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level in the hierarchy of evidence (Evans, 2003), and means that the studies focused clearly on 
the effectiveness of domperidone in increasing maternal milk production, rather than examining 
its use in clinical practice, or using anecdotal evidence. RCTs are currently considered to be the 
least biased type of study and to yield the strongest evidence of effectiveness of an intervention 
(Johnston, 2005). All four studies were single centre studies, and all were relatively small, with 
participant numbers ranging from six to 46 women. This places them at a level 3 out of 5 on the 
hierarchy of evidence scale (Ciliska, Thomas, & Buffet, 2008), and suggests that further research 
with larger numbers of participants with a multi-centre approach would be valuable in 
confirming efficacy as well as determining risks and side effects. 
There has not been any research done regarding the use of domperidone with mothers of 
older infants. Perhaps this is not a common use of domperidone: certainly the practitioners that 
were interviewed for this paper only spoke of use during the newborn period. This is not to say 
that this use does not occur, simply that I was not able to find any information, anecdotal or 
otherwise, regarding the use of domperidone with older infants. 
Analysis of Clinical Practice Guidelines 
The guideline from the Academy of Breastfeeding Medicine (ABM) is " Protocol #9: Use 
of galactogogues initiating or augmenting maternal milk supply", and is the only clinical practice 
guideline currently available for clinicians regarding prescribing of galactagogues. Until 
recently, this guideline was available for viewing on the both the National Guideline 
Clearinghouse (NGC) and ABM websites, however the NGC has recently removed the guideline 
from their website. The NGC states that: 
Guideline summaries are removed from the NGC Web site because they no longer meet 
the NGC Jnclusion Criteria with respect to date, or because the guideline developer has 
indicated that the clinical practice guideline upon which the summary is based is 
obsolete, should no longer be used, or has not yet been replaced with a new/revised 
guideline. 
(NGC, 2010) 
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A critical analysis of this guideline using the Appraisal of Guidelines for Research & Evaluation 
(AGREE) Instrument (The AGREE Collaboration, 200 I), reveals many flaws and gaps, which I 
will outline below. 
The first issue that I uncovered with this critique of the guideline was the lack of 
multidisciplinary input, despite the wide range of health care providers who would be accessing 
these guidelines. There is no input from health care professions such as pharmacists, nurses, or 
lactation consultants despite their obvious role in breastfeeding success. In fact, there were only 
four people on the committee for these guidelines, and all are fellows with the ABM. 
A second concern is the lack of any type of decision-making tool for clinicians, and no 
patient information handouts. Essentially the guideline consists of a brief summary of research, 
or expert consensus when no research is available, with no clarification as to how this 
information should be used in practice. There is a lack of information regarding appropriate 
follow up for treatment recommendations, expected outcomes, or possible barriers to treatment 
such as cost and availability. 
Finally, several herbal preparations are discussed in the guideline, despite the lack of 
evidence of their safety or efficacy. The references for the herbal recommendations are the 
anecdotal references discussed earlier in this paper (Co, Hernandez, and Co, 2002; Huggins; n.d.; 
Low Dog, 2001; Swafford & Berens, 2000), and the Huggins reference is the only one easily 
accessible online. The presentation by Low Dog is no longer available (T. Low Dog, personal 
communication, June 7, 201 0), and there is no contact information for Co et al.: however, I was 
able to obtain the Swafford and Berens paper via personal communication. The inability to 
actually find the references used does not seem appropriate for a clinical practice guideline, 
and the use of these references could lead the undiscerning practitioner to assume that there is 
evidence to support the use of these herbal preparations, when in fact this is not the case. 
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Despite these flaws, the ABM guideline is cited in the Fraser Health Breastfeeding 
Guidelines (Fraser Health Authority, 2008), and in much of the literature (Hsi & Leeman, N.D.; 
Mallory, 2008; Marasco, 2007; Shealy, Li, Benton-Davis, and Grummer-Strawn, 2005). There 
are no Canadian CPGs, but much of the recent research on galactagogues has come from Canada 
(Brown, et al., 2000; Campbell-Yeo et al., 20 10; DaSilva et al., 2001 ). 
Implications for Practice 
Galactagogues should not be a first line treatment for possible breast milk insufficiency. 
The practitioner must first determine whether the insufficient maternal milk supply is a perceived 
problem or an actual problem. If it is an actual problem then it must be determined which of the 
three categories of causes is the basis of the problem: primary failed or delayed lactogenesis II; 
secondary delayed lactogenesis related to breastfeeding management or breast milk transfer 
issues; or organic failure to thrive, with newborn pathology. There are no guidelines currently 
available to aid with this determination, nor with what assessments and interventions should take 
place prior to prescribing galactagogues. 
The recommendations that follow reflect the available evidence, and focus on the first 
several weeks following delivery rather than older infants. There is perhaps an assumption that 
breast milk insufficiency is more urgent in the initial weeks following birth, when all of the 
infant's nutritional needs are expected to be met by breast milk, rather than in older infants who 
may be consuming solid foods in addition to breast milk. However, it is reasonable to assume 
that an NP faced with the possibility of decreased breast milk supply in the mother of an older 
infant could perform the same assessments and interventions recommended below, with the 
understanding that congenital newborn conditions are unlikely to appear at this point. Rather, 
issues of maternal hormonal conditions, the introduction of new maternal medications, or 
changes in feeding patterns are much more likely. 
Assessment of Maternal Milk Supply 
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So what assessments should be performed by the NP when a woman presents with the 
chief complaint of "I don't have enough milk to feed my baby"? The initial issue is whether or 
not the milk insufficiency is a perceived or actual problem. This is quite easily determined with 
the following assessments. The infant's weight should be assessed and weight should be plotted 
serially on a growth chart to track patterns ofweight change. A weight loss of5-10% can be 
normal in the first three to four days after birth, however breastfeeding should be assessed when 
infant has lost more than 7% (BCPHP, 1997; Health Canada, 2007; Mohrbacher & Stock, 2003). 
The baby should regain birth weight by two to three weeks after birth (BCPHP, 1997; Health 
Canada, 2007; HealthLink BC, 2009; Mohrbacher & Stock, 2003). Weight gain thereafter 
should be approximately 120 to 180 grams per week, or 17 to 26 grams per day for the first three 
to four months of life (BCPHP, 1997; Health Canada, 2007; La Leche League International 
(LLLI), 2007; Mohrbacher & Stock, 2003). 
Second, the output of the baby should be assessed. By day 5, baby should be having at 
least six wet diapers every day and the urine should be clear or light yellow in colour, not dark or 
odorous. There should also be two to five quarter-sized bowel movements daily. The baby must 
also be assessed for signs of dehydration such as lethargy, poor skin turgor, sunken fontanelles, 
jaundice, dry mucous membranes and eyes, or fever (BCPHP, 1997; Health Canada, 2007; 
Health Link BC, 2009; LLLl, 2007; Mohrbacher & Stock, 2003). 
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Should it be determined that the baby is not gaining weight adequately, does not have 
sufficient output, and or shows signs of dehydration, it must be determined whether this is an 
issue of insufficient milk supply or poor milk transfer. The LATCH breastfeeding assessment 
tool has been found to be a valid tool for assessing breastfeeding latch both in the hospital and 
community settings, and is recommended to flag women and baby dyads who are at increased 
risk for early weaning due to nipple discomfort (Riordan, Bibb, Miller, & Rawlins, 2001). 
Improper latch can lead to inadequate emptying of the breast, in turn leading to decreased milk 
production as well as inadequate infant intake (Hurst, 2007). Therefore, a tool to assess latch is 
an important aspect of primary care breastfeeding management, and should be used to determine 
adequacy of breastfeeding sessions. 
The LATCH tool is a relatively quick measurement of latch that primary health care 
providers may find helpful in assessing latch and determining if this is the cause of poor infant 
breast milk intake. Should the nurse practitioner find that the latch score identifies concerns with 
the latch such as poor infant suck, a tongue-tie, or flat to inverted nipples then this can be further 
assessed and dealt with by the practitioner. If he or she is not competent or comfortable in this 
area, then referral to another resource such as a lactation consultant, breastfeeding counselor, or a 
La Leche League representative should be considered , subject to availability. Discussion of how 
to correct problems with latch is beyond the scope of this project. 
If breast milk transfer is found to be adequate using a latch assessment tool, but the infant 
is not gaining weight appropriately, or is losing weight, then the issue is more likely to be related 
to breast milk production, which is estimated to affect 5-15% of breastfeeding women (Hurst, 
2007). Hurst notes that primary lactation failure can be related to conditions such as "anatomic 
breast abnormalities or hormonal aberrations. Insufficient mam mary glandular tissue, 
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postpartum hemorrhage with Sheehan syndrome, theca-lutein cyst, polycystic ovarian 
syndrome, and some breast surgeries" (Hurst, 2007, p. 590). The process of diagnosing any of 
these conditions requires a thorough history and physical examination, which should include the 
details of the pregnancy, labour and delivery. Laboratory tests should be ordered to check for 
any hormonal irregularities, and the specific tests and assessments will vary depending on what 
diagnoses are being ruled in or out. 
Secondary lactation failure in the first six weeks postpartum can be related to poor latch 
as mentioned above, as well as the over-use of pacifiers, restrictive feeding schedules rather than 
baby-led feeding, supplementary feeds, and some maternal medications such as oral 
contraceptives (Hurst, 2007). Once again, a thorough history that includes a review of all 
medications and herbs is required to assess for this, along with detailed recall of feeds and use of 
pacifiers and supplements. Secondary lactation failure can and should be managed with 
education regarding the use of pacifiers, supplementary feeds, and restrictive feeding schedules 
and how these can interfere with breast milk production. Maternal medications that are found to 
be interfering with milk supply should be discontinued if possible, and alternative treatments 
found. 
Primary lactation failure requires treatment of the underlying cause. Treatment of both 
primary and secondary lactation failure should be accompanied by increased breast stimulation, 
i.e. infant suckling at the breast and or pumping the breasts, and increased breast emptying to 
stimulate milk production (Hurst, 2007). Only after these measures have been implemented 
should the use of pharmaceutical galactagogues be considered, and only with close follow up and 
re-assessment within two to three days. 
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NP Scope of Practice 
The prescribing of domperidone is within the scope of practice for NPs in BC (The 
College ofRegistered Nurses of British Columbia (CRNBC), 2010), however the assumption in 
the scope of practice document is that the domperidone is being prescribed for its approved use 
as a gastrokinetic medication. So what does the legislation say regarding NP prescribing of 
medications for off-label purposes, which is to say, prescribing a medication for its side effects 
rather than its approved purpose? 
The CRNBC does not directly address the subject ofNPs prescribing medications for off-
label uses, however there are examples in grey literature (Keith, 2007) as well as in family NP 
practice in BC (C. Evanson, personal communication, June 3, 2010; C. Lapadat, personal 
communication, March 12, 2010; V. Stafford, personal communication, March 23, 2010). 
Consulting with the CRNBC N P practice consultant regarding this issue revealed that as long as 
the standards of practice are met, in this case the standards under section B of the scope of 
practice document "Prescribing and Dispensing Drugs", then off-label prescribing is an 
acceptable practice (CRNBC, 20 I 0; A. Komaryk, personal communication, May 11 , 20 l 0). In 
the UK, NPs may prescribe medications for off-label uses where this is common practice (Drug 
and Therapeutics Bulletin, 2006). There is no official Health Canada or Canadian Medical 
Association policy on off-label medication prescribing (Silversides, 2006): however, it is 
acknowledged that this is common practice. This is mainly due to the logistics of obtaining 
approval to market a drug for a second purpose, which can take years (Canadian Broadcasting 
Corporation News, 2008). The US FDA also acknowledges this as common practice among 
prescribers and recommends that the prescriber must have excellent knowledge of the 
medication, and that the off-label use of any medication should be evidence-based (2009). 
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Despite the absence of any actual policies regarding off-label prescribing, there does 
not appear to be any official reason for nurse practitioners not to prescribe medications for off-
label use. This is provided that there are no known contraindications in the patient's history, that 
they are practicing within their scope of practice, have an excellent understanding of the 
pharmacodynamics, pharmacokinetics, expected therapeutic effect, and possible adverse effects 
of that drug, as well as compelling evidence of the drug 's safety and efficacy when used for this 
purpose. 
Recommendations 
There is an abundance of evidence that suggests that well-informed primary care 
providers with education and training regarding lactation is one of the most important and 
influential factors in increasing breastfeeding initiation, success, and duration rates (ABM, 2006; 
Chung et al., 2008; Couto De Oliveira, Bastos Camacho, & Tedstone, 2001; Dennis, 2002; 
Dyson et al., 2009; Eglash et al., 2008; Gill, Reifsnider, & Lucke, 2007; Hurst, 2007; Porteous, 
Kaufman, & Rush , 2000; Shealy et al., 2005; Sikorski, Renfrew, Pindoria, & Wade, 2003). 
All primary health care providers, including nurse practitioners, should ensure that they 
have an adequate knowledge base to discuss benefits to mother and baby of breastfeeding, the 
risks associated with formula feeding, and the current cost of formula in their community. They 
should have sufficient knowledge to assess breastfeeding technique, in other words, latch and 
milk transfer, and they should be confident with methods to intervene when there are problems 
with latch or milk transfer (PHAC, 2002). 
I believe that this should be incorporated into the curriculum of all primary health care 
providers, including nurse practitioners. WHO/Unicef has developed a 20 hour breastfeeding 
course that teaches health care providers lactation management and The Infant Feeding Action 
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Coalition (INF ACT) Canada offers this course frequently (INF ACT Canada, 201 0; Unicef, 
2009). This course should be included as part of the basic curriculum for nurse practitioners, 
particularly those in the family and pediatric streams of practice. The importance of 
breastfeeding as primary health care promotion cannot be overemphasized, and it should be 
given more time in health care provider education than it currently receives. In my nurse 
practitioner program, management of breastfeeding problems was simply one of twenty learning 
objectives in one week of class. This cannot be considered adequate in light of the frequency 
with which breastfeeding issues such as perceived or actual insufficient milk supply lead to 
discontinuation of breastfeeding (Millar & Maclean, 2005). There was no information available 
regarding number of hours spent learning about breastfeeding in other primary care provider 
courses. 
Research should be actively pursued with regard to the most commonly-prescribed 
galactagogues, domperidone and fenugreek. For the women who demonstrate actual insufficient 
milk supply, with infants showing nutritional insufficiency when all other causative factors have 
been ruled out, domperidone may mean the difference between being successful at breastfeeding, 
or having to supplement with formula. This is of huge impot1ance to these women and families 
on a personal level, and to Canadians overall as a public health issue. As discussed earlier, the 
short and long term benefits to mother and baby are significant, and for this reason the use of a 
safe and effective galactagogue is relevant and important. 
What is missing from the recommendations regarding herbal treatments as galactagogues 
is evidence. There are a number of reasons for this. The first is that companies that market 
herbal over-the-counter remedies are not required to follow the same rigorous process as 
manufactured pharmaceuticals. It does not make much sense to spend money on expensive trials 
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if it is not required in order to sell your product. The second is the perpetual myth that 
somehow herbal remedies are safer and less toxic than pharmaceuticals. Those who market 
herbal preparations point out that these herbs have been used for generations, with plenty of 
anecdotal evidence to back them up. A third is the current organic and natural trend discussed 
earlier, which favours herbs and supplements, vilifying mega-corporations such as 
pharmaceutical companies, and encouraging a more natural approach to all aspects of life. What 
is not considered is the stringent guidelines and safety testing that is required for pharmaceuticals 
and is not required for herbal remedies. I would suggest that requiring the same standardization 
and testing for safety and efficacy with herbal products would help NPs to make informed 
decisions regarding their use, and to offer education and guidance to their patients. NPs, as 
holistic health care providers, may have a special interest in pushing for these types of 
regulations at a policy level in Canada. 
The lack of research regarding safety of herbal preparations simply means that there is no 
record of adverse events, not that those event do not occur. People are living longer, and with a 
better quality of life thanks to pharmaceuticals and the research that they inspire, and this is what 
many proponents of the natural /organic movement forget. The medications produced must be 
efficacious, tolerable, and safe, or the pharmaceutical companies do not make any money from 
them, because health care providers do not continue to prescribe questionable or poorly tolerated 
medications to their patients. 
The promotion of herbs by high profile figures such as Jack Newman help to perpetuate 
the myth that somehow herbal remedies are safer and less toxic than pharmaceuticals. Jack 
Newman is a well-respected physician and crusader for breastfeeding, which is admirable, but 
the complete lack of references or research on his websites and handouts, which are easily 
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accessible by the public, cannot be overlooked (Newman, 2003a; Newman, 2003b). Herbal 
preparations such as fenugreek and blessed thistle have not been subjected to the same rigorous 
testing as pharmaceutical galactagogues and therefore their efficacy, safety, and even 
recommended dosage have not been agreed upon in the literature (Abascal & Yarnell, 2008; 
Curtis, n.d.; Health Canada, 2009; Huggins, n.d.; Lagrave, n.d. ; Laurence, n.d.; Low Dog, 2009; 
Marasco, 2007; Mills , Duguoa, Perri , & Koren, 2006; Newman, 2003a; Tiran, 2003; Ulbricht et 
al. , 2007) 
Alcohol has not shown any efficacy as a galactagogue, and due to potential for side 
effects for the infant as well as the potential for abuse, using alcohol as a galactagogue should be 
actively discouraged. Patients should be educated regarding the demonstrated decrease in breast 
milk consumption by infants whose mothers drink even moderate amounts of alcohol prior to 
breastfeeding, which suggests alcohol is actually counter-productive as a galactagogue 
(Mennella et al. , 2005). 
There is limited evidence regarding acupuncture, but what is available is compelling, and 
the safety profile is excellent. Further research should be done with regard to efficacy, but as a 
complementary alternative therapy there is no reason to actively discourage its use. 
Metoclopramide does seem to demonstrate effectiveness with increasing prolactin levels, 
but the increased incidence of side effects, and in particular the ability of metoclopramide to 
cross the blood-brain barrier and cause extrapyramidal side effects makes it a less-attractive 
choice. The continued use of metoclopramide as a galactagogue in the US likely has more to do 
with the difficulty obtaining domperidone and with the FDA warning, than with any practitioner 
preference for this drug. 
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The research on domperidone is ongoing, and the drug also appears to have efficacy 
with regard to increasing prolactin levels and thereby milk supply, however, prolactin levels are 
only one factor in breast milk production, which is why an adequate knowledge base in 
lactogenesis and management of common breastfeeding problems as well as how to intervene 
with them must accompany any pharmaceutical intervention. Larger scale studies would be 
beneficial, particularly with regard to the safety profile of domperidone in light of the US FDA 
warning against its use in any capacity. In the meantime, domperidone is commonly used in 
Canada as a galactagogue, with no reported safety concerns. There is no apparent reason to not 
use domperidone as the research currently available is compelling, provided that other possible 
causes of insufficient nutritional status of the newborn have been ruled out or identified and 
addressed. Cost is not prohibitive at less than two dollars per day for a dosage of 10 mg four 
times daily (Maclean, 2007). The cost of formula is approximately $2.50 to $3.50 per day 
depending on the brand (Skelton, 2009), so when one considers the health benefits of 
breastfeeding compared with formula feeding, using domperidone to increase breastfeeding 
success is a very feasible intervention , and in fact is a better and less-expensive option than 
supplementing with formula. 
If domperidone is appropriate, then the research to date suggests that a dosage of I 0 mg 
orally three times daily for two weeks is likely to be effective, while minimizing possible side 
effects (Campbell-Yeo et al., 2010; DaSilva et al., 2001; Wan et al., 2008). Follow up with the 
mother and baby should involve infant weights, serial plotting on a growth chart, and 24 hour 
surveillance of the newborn 's output. The frequency of follow up is at the discretion of the NP 
with consideration to the specific circumstances of each case. The mother must be educated 
regarding the feedback mechanism involved in autocrine control of breast milk production, 
and ensure that her breasts are adequately emptied on a frequent basis to facilitate this. 
Conclusion 
The benefits of breastfeeding in newborns include decreased incidence of infections, 
allergies, SIDS, and potential improvement in cognitive development (PHAC, 2009; Health 
Canada, 2005; Health Canada, 2007; Kramer & Kakuma, 200 I). Long term benefits for adults 
breastfed as infants include lower blood pressure, lower cholesterol, lower incidence of obesity 
and type 2 diabetes mellitus (Horta et al., 2007; Martinet al. , 2005). Maternal benefits include 
decreased incidence of some cancers and osteoporosis, increased weight loss in the postpartum 
period , and decreased cost. Environmental benefits include no packaging, waste or processing. 
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These benefits are well-known, and the societal pressure to breastfeed is enormous. This 
has led to an increase in the request for galactagogues by breastfeeding women and their 
families, and the NP as primary health care provider should be prepared to prescribe 
galactagogues appropriately and safely. This requires adequate knowledge of the physiology of 
breastfeeding, of the causes of lactation failure, and adequate assessment of breastfeeding latch 
and milk transfer using validated tools. It also requires vigilance with regard to current 
literature, and critical analysis of all recommendations to ensure that they are up to date, and that 
the evidence presented is based on adequate and well-done research. 
There are no herbal remedies that have been studied adequately enough to recommend 
their use in primary health care. The two drugs that have been studied and thus far demonstrate 
efficacy in increasing maternal milk supply are domperidone and metoclopramide. 
Domperidone is the more commonly used in Canada, due to its decreased incidence of side 
effects when compared to metoclopramide. The prescribing of domperidone must be 
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accompanied by counseling regarding breastfeeding technique and the need for baby-led 
feeding versus scheduled feeding, and avoidance of the use of supplementary feeds or pacifiers. 
As well , women who are prescribed domperidone should be followed closely, within two to three 
days, and infants must be watched closely for signs of improving intake, with closely supervised 
supplementation as required. 
[nsufficient milk supply is a complicated, multifactorial issue that women should not be 
expected to cope with alone. This requires intensive follow up with a health care provider that is 
well-educated and confident regarding breastfeeding assessment and intervention. The 
perception that breastfeeding is a natural process is possibly one that has led to the 
extraordinarily poor numbers of women who are able to meet the Health Canada (2004) 
recommendations for exclusive breastfeeding duration (Millar & McLean, 2005). Domperidone 
is currently the only galactagogue that demonstrates efficacy along with an acceptable side effect 
profile, but this drug should not be prescribed haphazardly or without close supervision. 
Domperidone should be used when deemed appropriate, with excellent assessment and 
follow up by an experienced, educated clinician. The best armament the primary health care NP 
has with regard to perceived or actual breast milk insufficiency is knowledge to ensure that this 
drug is used appropriately and only when absolutely required. The NP must be able to provide 
reassurance when no intervention is required , to provide excellent counseling regarding 
breastfeeding technique, and to confidently prescribe domperidone once the need is determined 
through thorough assessment. It must also be noted that NPs must support mothers who choose 
to bottle feed their infants, particularly in the face of societal , cultural, and government pressure 
to breastfeed. 
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There is plenty of evidence that support and education from primary health care 
providers is often all that is required to help women succeed with breastfeeding. Systematic 
assessment and therapeutic intervention using the algorithm in appendix A when the NP is faced 
with perceived or actual breast milk insufficiency will help to decrease the unnecessary use of 
galactagogues in practice, ensure that when they are used the dosage and monitoring of 
effectiveness is methodical and safe, and help to increase the rate of successful breastfeeding as 
per the Health Canada recommendations. 
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Appendix A: Algorithm for Assessment of Breast Milk Insufficiency in Newborn Period 
Clinical Presentation: 
Breast Milk Insufficiency 
I 
infant Wt gain appropriate? 
I Number of voids and stools I 
Yes adequate? [ No J Reassure mother and No supplementation with Determine Cause 
follow as per usual breast milk substitutes? 
I 
Breast Milk Metaboli.sm 
~Maternal Milk Production Issue 
Issue Milk Transfer Issue 
Congenital disorders 
1 Inborn Errors of Metabolism I I I r Maternal Endocrine ' Poor Latch: Disorder: Correct poor technique Rule out and treat prn 
Obesity Treat underlying cause such as May require breast milk ... Thyroid tongue-tie, cleft palate substitute 
Diabetes Mellitus Dompcridone not appropriate 
PCOS 
PPH ./ r ill frequent Feeds or \ 
Delayed Breastfeeding supplementation: 4 T re•t ""dodyiog diwroe< l Ensure at least 8 feeds per initiation: 
Consider Domperidone - 24 hrs and gradually Ensure frequency of feeds 
remove any supplemental adequate 
feeds, replace with BF Consider Domperidone 
'-... 
Consider Dornperidone 
Anatomical Breast 
Maternal Stressors: 
Abnormalities 
CIS, Prolonged 2"d stage 
of labour 
Personal stress 
Smoking 
OCP I" week postpartum 
\.. 
/Consider Dornpcridone \ 
/ Reassurance If not able to provide 
Counseling as indicated 
adequate amount of breast 
Smoking Cessation 
... milk, consider comfort - Switch to progesterone- feeding and 
only OCP 
supplementing with 
\.. Consider Domperidone 
formula 
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A d" B H b I G I t "ppen IX : er a a ac agogues 
Name 
Recommended Evidence to Side Effects 
Other Uses Dosage Support Use 
-Labour induction -Daily dosage -No RCTs -Maple syrup 
-improvement of recommendations -One large odour to urine, 
digestion, overall range from 400- anecdotal report sweat, and 
health and 2400mg, divided re: use with breastmilk 
metabolism into two or three over 1200 -Diarrhea 
Fenugreek - Treatment of doses daily women -Asthma 
(Trigo nella inflammation, -No consensus, -2 "preliminary aggravation 
foenum- abdominal pain, and no reports" given -Hypoglycemia 
graecum) impotence, hernias, standardization of at conferences -Uterine 
fever, vomiting, dosage in that are not contractions 
anorexia, weight loss, packaging obtainable -Increases effect 
coughs, bronchitis, of warfarin 
colitis 
Blessed 
-None, other than as -3 capsules 3 -Anecdotal -vomiting and 
Thistle 
galactagogue times daily OR only, no studies diarrhea 
(Cnicus 
-20 drops of 
tincture 3 times 
benedictus) 
daily 
- platelet aggregation -taken in tea form: -reports of -hypoglycemia 
inhibition, 1 tsp dried leaves increased milk -decreased 
antibacterial in 8 ounces water supply when calcium, 
Goat's Rue 
properties, and weight steeped for 10 min used in cows albumin, 
(Galega 
loss 2-3 times daily -no human hematocrit, 
OR studies white blood 
officina/is) 
-1-2m Is of tincture cells, and 
3 times daily platelets 
-None, other than as a -taken in tea form: -Small RCT in -No known side 
galactagogue I teaspoon Peru effects 
Milk Thistle 
crushed seeds in 8 demonstrated 
(Silybum 
ounces water significant 
steeped for 1 0 
. . 
marianum) 
111crease 1n 
minutes 1-3 times breastmilk 
daily. production 
-treatment of: colic -In tea form: 5- -No studies on -No known side 
Fennel Seed 
in infants, acute and 7gms of seeds galactagogue effects 
(Foeniculum 
chronic glaucoma, daily effects 
dementia, and 
vulgare) 
dysmenorrhea 
Chaste Tree - treatment of -as a tea, 1 -No studies that - GI upset, 
Seed premenstrual teaspoon of chaste demonstrate dizziness, 
(Vitex agnus- syndrome (PMS) and berries in one cup effectiveness headache, 
castw) premenstrual of water 3 times fatigue, and dry 
dysphoric disorder 
(PMDD) 
-treatment for 
menstrual cycle 
irregularities, and 
cyclical breast 
discomfort 
daily OR 
- 2.5 milliliters of 
tincture three 
times daily OR 
-20 to 40 mg per 
day 
Appendix C: Alternative Galactagogues 
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mouth 
-contraindicated 
during 
pregnancy 
Name of Treatment Common Recommendation Evidence to Support Use 
Alcohol 
Barley-based alcohol such as 
beer will increase milk supply 
and aid milk let-down reflex 
None. Studies show that 
alcohol decreases suckling-
induced prolactin production 
(not baseline prolactin) and 
oxytocin release, thereby 
inhibiting both milk 
production and milk let-down 
Acupuncture 
Acupuncture administered 3 
times per week for 2 weeks 
performed by qualified 
acupuncture therapist using 
disposable needles 
A single blind RCT showed 
increased infant weight gain 
and decreased need for 
supplementation with formula 
when acupuncture used to 
increase maternal milk supply 
Drug 
Metoclopramide 
Appendix D: Pharmaceutical Galactagogues 
Usual 
Indications 
-Treatment of 
delayed gastric 
emptying 
-Treatment of 
nausea and 
vomiting 
postoperatively 
Recommended 
Galactagogue 
Dosage 
10 mg orally 3 
times daily 
Adverse Effects 
- restlessness, 
anxiety, 
drowsiness, 
insomnia, fatigue, 
lassitude, dizziness, 
and GI effects such 
as cramping and 
diarrhea 
-may also increase 
maternal depression 
and risk for seizures 
-Rarely can have 
extrapyramidal side 
effects, including 
dystonic reactions 
Evidence to 
Support Use 
-Conflicting 
evidence, with 
much of the cited 
research being 
done before 2000 
-2 recent studies 
did not show . . 
mcrease m 
breastmilk 
production or 
infant weight 
gain with 
metoclopramide 
use 
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- treatment of -wide disparities -dry mouth, -2 double-blind 
nausea and in dosage, abdominal RCTs since 2000 
vomiting, gastro literature notes cramping, demonstrate 
paresis, range of30- headache, and significantly 
dyspepsia, and 90mg per day in diarrhea increased 
esophageal 2-4 divided -does not cross the prolactin levels 
reflux doses blood/brain barrier and breastmilk 
-Latest evidence so no CNS effects volume 
suggests (measured by 
Domperidone 
30mg/day pumping) in 
adequate, with women given 
larger doses domperidone 
increasing side 
effects but not 
therapeutic 
effect 
-Common local 
practice is I 0-
20mg 2-4 times 
daily 
-None, other -Test subjects -No significant -Double-blind, 
than as potential were injected adverse effects placebo-
galactagogue subcutaneously observed controlled RCT 
(experimental) once daily for 7 done in 2007 on 
recombinant days non-lactating 
human prolactin women 
(r-hPRL) demonstrated 
expressible 
galactorrhea in 
test subjects 
given r-hPRL 
-Antipsychotic -50 mg orally 2- - sedation, weight -No studies since 
-Not available in 3 times daily gain, depression, 2000, and studies 
Canada restlessness, done prior to this 
Sulpiride 
impaired found to have 
concentration, and methodology-
extrapyramidal Issues 
effects 
-Antipsychotic -25 mg orally 3 -see sulpiride -No studies 
Chlorpromazine 
times daily for I available for use 
week as a galactagogue 
66 
A d" E Th LATCH B ,ppen IX : e reas U d" A ee mg ssessment T 00 
0 1 2 
Too sleepy or reluctant Repeated attempts Grasps breast 
L: Latch No latch achieved Hold nipple in mouth Tongue down 
Stimulate suck Lips flanged 
Rhythmic sucking 
A: Audible None A few with Spontaneous and 
swallowing stimulation intermittent at <24 
hours 
Spontaneous and 
frequent at >24 hours 
Inverted Flat Everted (after 
T: Type of nipple stimulation) 
C: Comfort Engorged Filling Soft 
(breast/nipple) Cracked/bleeding/large Reddened/small Non-tender 
blisters or bruises blisters or bruises 
Severe discomfort Mild/moderate 
discomfort 
Full assist (staff holds Minimal assist No assist from staff 
H: Hold (positioning) infant at breast) Teach one side, Mother able to 
mother does other position/hold infant 
Staff holds and then 
mother takes over 
(Jensen et al. , 1994) 
